NEW YORK (GenomeWeb News) — IMDx said today that its IMDx VanR assay for the Abbott m2000 platform has received regulatory clearance from Health Canada and Singapore's Health Sciences Authority, allowing the test to be sold and distributed in those countries.
As one of its major molecular diagnostics-related revenue sources begins to slow down, Qiagen today outlined its plan to replace it with several new MDx initiatives and other molecular biology-related growth drivers.
The collaboration will combine microfluidic PCR technology licensed from Caliper Life Sciences and various innovations from Canon's imaging and printing products with sample prep, digital PCR, and sequencing components from UMD researchers.
The new funds follow a $3.3 million Series C financing round closed in late 2009. MDI will use the money to further develop its pipeline of qualitative real-time PCR in vitro diagnostic tests for infectious diseases.
Cepheid also recently inked sole-source agreements with two separate entities to conduct surveillance of methicillin-resistant Staphylococcus aureus using its GeneXpert platform, company officials said last week.